english.prescrire.org > Prescrire International > N°149 - May 2014

n°149

May 2014

Issue Contents
Editorial

Free  Mythologising

p.116
Personification of drugs diverts attention from patients

Marketing Authorisations


Lorcaserin

p.117-120
In obesity: unacceptable risks

"Selectivity": an attractive but often misleading notion

p.120

Tapentadol

p.121-124
Acute or chronic pain: no therapeutic advance

Tenofovir in HIV-infected children (New Indication)

p.124-125
Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys

INN common stem: -cept

p.125

Adverse Effects


Nicotine replacement products: poisoning in children

p.126-128
Keep out of the reach of children, even after use

The pharmacology of nicotine in brief

p.127

Gliptins: severe pancreatic and cutaneous disorders

p.128
It is best not to use these drugs

Free  Benfluorex: left heart valve disease very common (continued)

p.128
Echocardiographic study

Free  Antiseptics: sometimes the cause of infection

p.129
Single-use containers are safer

Free  Antithrombotic and cytotoxic drugs: too often fatal

p.129
Drug-related hospital deaths

Free  Mirtazapine: rhabdomyolysis

p.129
Reports from the WHO database

Reviews


Bleeding associated with uterine leiomyomas

p.130-135
Tailor treatment to the individual patient

Uterine artery embolisation: an alternative to surgery?

p.133

Outlook


Free  Drug packaging in 2013: small changes would reap big benefits

p.136-139
Regulators and manufacturers must take action

Free  Prescrire's Red Cards for drug packaging, 1991-2012: some improvements, but many dangers persist

p.139

Masthead


Free  Masthead

p.114

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe